Figure.
Forest plot highlighting the association of genetically proxied lipid-lowering drug targets and ischemic stroke across the European (Eur) and African (Afr) ancestry populations. No significant association was found in Africans; however, same direction of effect was observed (odds ratio [OR], 1.10 [95% CI, 0.763–1.600]; P=0.616). APOB perturbation showed no significant association with risk of ischemic stroke in both European (OR, 1.039 [95% CI, 0.934–1.157]; P=0.477) and African ancestries (OR, 1.097 [95% CI, 0.473–2.547]; P=0.828). The findings of the MR-Egger, weighted median, and weighted mode sensitivity analyses revealed consistency in the effect estimates for all 3 techniques. We did not detect any evidence of heterogeneity in the 3 genes in African ancestry individuals, but some heterogeneity was detected in LDLR (low-density lipoprotein receptor) and PCSK9 (proprotein convertase subtilisin/kexin type 9) in the European ancestry. F indicates F statistics; IVW, inverse variance weighted; MR, Mendelian randomization; MR-PRESSO, Mendelian Randomization Pleiotropy Residual Sum and Outlier; Phet, P value for heterogeneity; and PVE, percentage variance explained.